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Background: Recent studies involving phototherapy applied prior to exercise have demonstrated positive results
regarding the attenuation of muscle fatigue and the expression of biochemical markers associated with recovery.
However, a number of factors remain unknown, such as the ideal dose and application parameters, mechanisms of
action and long-term effects on muscle recovery. The aims of the proposed project are to evaluate the long-term
effects of low-level laser therapy on post-exercise musculoskeletal recovery and identify the best dose and
application power/irradiation time.
Design and methods: A double-blind, randomized, placebo-controlled clinical trial with be conducted. After fulfilling
the eligibility criteria, 28 high-performance athletes will be allocated to four groups of seven volunteers each. In phase
1, the laser power will be 200 mW and different doses will be tested: Group A (2 J), Group B (6 J), Group C (10 J) and
Group D (0 J). In phase 2, the best dose obtained in phase 1 will be used with the same distribution of the volunteers,
but with different powers: Group A (100 mW), Group B (200 mW), Group C (400 mW) and Group D (0 mW). The
isokinetic test will be performed based on maximum voluntary contraction prior to the application of the laser and after
the eccentric contraction protocol, which will also be performed using the isokinetic dynamometer. The following
variables related to physical performance will be analyzed: peak torque/maximum voluntary contraction, delayed
onset muscle soreness (algometer), biochemical markers of muscle damage, inflammation and oxidative stress.
Discussion: Our intention, is to determine optimal laser therapy application parameters capable of slowing down the
physiological muscle fatigue process, reducing injuries or micro-injuries in skeletal muscle stemming from physical exertion and
accelerating post-exercise muscle recovery. We believe that, unlike drug therapy, LLLT has a biphasic dose–response pattern.
Trial registration: The protocol for this study is registered with the Protocol Registry System, ClinicalTrials.gov identifier
NCT01844271.
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Muscle fatigue is a dynamic, time-dependent failure to
maintain a desired level of yield or work during a repeti-
tive or sustained activity [1]. Fatigue has a central and
peripheral component, both of which affect the produc-
tion of force during muscle performance. The decline in
muscle activity varies in accordance with the type of
muscle fiber and intensity of the exercise [2,3]. Fatigue
can also contribute to the development of muscle dam-
age, which is characterized by an inflammatory response
[4,5], an increase in muscle proteins in the blood [6] and
late-onset muscle pain [7-9]. These events occur in a
more accentuated fashion when eccentric contractions
are employed [6,10,11].
High-performance athletes are prone to muscle dam-
age stemming from training and competition, comprom-
ising their performance for a given period of time, which
can range from minutes or hours to several days or even
months [12]. A large number of therapies are currently
employed after sport activities to enhance muscle recov-
ery, such as active recovery [13-15], cryotherapy [9,16],
stretching [12] and electrical stimulation [17]. The aim
of post-exercise therapy is to reverse muscle damage,
with no attempt made to prevent or attenuate the occur-
rence of muscle damage.
Recent studies by our research group involving low-level
laser therapy (LLLT) and LED therapy have demonstrated
positive results when applied prior to exercise, with the at-
tenuation of muscle fatigue [18-24] and favoring the re-
covery of biochemical markers related to muscle damage
[25-27]. The findings suggest that LLLT can minimize the
occurrence of injury and optimize an athlete’s return to
his/her activities in a shorter period of time.
Despite the positive results obtained in the studies cited
above, a number of variables remain unknown, such as
the ideal dose and application parameters, mechanisms of
action and long-term effects on muscle recovery. Based on
our line of research, LLLT is a valuable tool for the attenu-
ation of muscle fatigue and the acceleration of post-exercise
muscle recovery. As the same biphasic dose–response pat-
tern has been seen in other musculoskeletal disorders and
both power and irradiation time exert an influence on the
efficacy of therapy, these outcomes justify the development
of the proposed study.
Methods and study design
Characterization and purpose of study
A double-blind, placebo-controlled, randomized, clinical
trial will be carried out in two phases. The study will be
conducted at the Laboratory of Phototherapy in Sport
and Exercise at Nove de Julho University (UNINOVE) in
the city of São Paulo, Brazil. The project has received
approval from the Human Research Ethics Committee
of the university under protocol number 397774/2011and the study is supported by a Young Researcher award
grant from the Brazilian fostering agency, Sao Paulo Re-
search Foundation (FAPESP), under process number
2010/52404-0.
Characterization of sample
Twenty-eight male high-level soccer athletes from the
same team will participate in each phase of the study.
The decision to recruit volunteers from the same team
was made to enhance the homogeneity of the sample.
For recruitment of volunteers an initial contact will be
made with head coaches of several Brazilian soccer
teams. If the head coach accepts that the team can be
part of the study, then a personal invitation will be made
for athletes individually. Afterwards, the research team
will ask athletes about their personal data in order to
identify if they meet the inclusion criteria or if they need
to be excluded from the clinical trial.
Calculation of sample size
The sample size was calculated based on a previous
study [28], in which a similar experimental model and
exercise protocol was employed as that to be used in the
proposed study. The sample size calculation considered
a β of 20% and α of 5%. In the study used as reference
for this calculation of Baroni et al. [28], LLLT led to the
post-exercise recovery of creatine kinase (CK) (muscle
injury marker) to 435.95 U/l (standard deviation: 238.04),
whereas placebo treatment led to an increase in CK to
1,327.58 ± 949.82 U/l. Using these parameters, a total of
seven volunteers would be needed for each of the four
groups in each phase of the study (total of 28 volunteers
per phase).
Inclusion criteria
The following inclusion criteria will be employed:
 Professional soccer athletes;
 Age between 18 and 35 years;
 Male gender;
 Minimum of 80% participation in team practice
sessions;
 Light or intermediate skin color [29];
 Agreement to participate through signed statement
of informed consent.
Exclusion criteria
Participants with the following will be excluded from
the study:
 History of musculoskeletal injury to hips or knees in
the previous 2 months;
 Use of pharmacological agents or nutritional
supplements;
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the study;
 Any change in practice routine in relation to the
rest of the team during the study.
Composition of groups and randomization process
The volunteers will be randomly allocated to four experi-
mental groups (n = 7 per group) based on the LLLT dose
(phase 1) and power (phase 2) (Figure 1). Randomization
will be carried out by a simple drawing of lots (A, B, C or
D). The laser unit will emit the same sound regardless of
the programmed power output. Randomization labels will
be created using a randomization table at a central office,
where a series of sealed, opaque, numbered envelopes will
be used to ensure confidentiality. Randomization will be
conducted by a participating researcher, who will have the
function of programming the laser device based on the
randomization results. This researcher will be instructed
not to inform the participants or other researchers regard-
ing the LLLT dose (phase 1) or power (phase 2) until the
study has been completed. Thus, the researcher in charge
of the administration of the LLLT will be blinded to the
dose and power applied to the volunteers.
Experimental protocol
Evaluations and informative procedures
Evaluations will be carried out before and at the end of the
isokinetic protocol by a researcher blinded to the LLLT
dose (phase 1) and power (phase 2). The volunteers will
then be informed about the procedures and will sign a
statement of informed consent in compliance with Reso-
lution 196/96 of the Brazilian National Board of Health
prior to the execution of the study. All individuals in both
phases will be submitted to the same evaluation protocol,
which will involve the aspects described below.
Personal data
A questionnaire will be administered addressing age
(years), body mass (kilograms), height (centimeters),
dominant lower leg, schooling (no schooling, elementary
school education, high school education, university edu-
cation or postgraduate degree) and marital status (single,
married or widowed).
Blood samples and biochemical analyses
Following the informative process and randomization,
blood samples (10 ml) will be collected from the antecu-
bital vein before and 1 minute after the eccentric con-
traction protocol. Blood samples will also be collected 1,
24, 48, 72 and 96 hours after the protocol. The samples
will be taken by a nurse blinded to the allocation of the
volunteers to the four experimental groups. One hour
after collection, each sample will be centrifuged at 3,000
rpm for 20 minutes. Pipettes will be used to transferthe serum to Eppendorf® tubes (Eppendorf, Hamburg,
Germany), which will be stored at −80°C until analysis.
Blood analysis will involve the determination of CK and
lactate dehydrogenase (LDH) activity as indirect markers
of muscle damage, using spectrophotometry and spe-
cific reagent kits (Labtest Diagnóstica, Lagoa Santa, MG,
Brazil); IL-1β, IL-6 and TNF-α levels as inflammatory
markers, using ELISA and specific reagents (R&D Systems,
Minneapolis, MN, USA); and thiobarbituric acid reactive
substances (TBARS), carbonylated proteins, catalase (CAT)
and superoxide dismutase (SOD) as markers of oxidative
stress, using spectrophotometry and specific reactions.
Evaluation of delayed onset muscle soreness (DOMS)
Delayed onset muscle soreness (DOMS) will be evalu-
ated based on the pressure pain threshold, using an ana-
log algometer (Baseline®, Rome, Italy). This device
consists of a rod with a rounded rubber tip coupled to a
pressure (force) meter. The display presents values in ki-
lograms. As the surface of the rubber tip measures 1
cm2, the reading is expressed in kilograms per square
centimeter (kg/cm2). Values range from 0 to 10 kg, with
a precision of 0.1 kg. The most sensitive areas of the
knee extensors (medial, lateral and central) of the non-
dominant lower limb will be located through palpation
by an examiner blinded to the allocation of the volun-
teers to the different groups and will be marked with a
dermographic marker. The cylindrical end of the equip-
ment will be positioned perpendicularly to the demar-
cated area. Pressure will be applied to the surface of the
skin with a gradual increase in increments of 0.1 kg. The
volunteers will be instructed to say ‘yes’ when the pres-
sure exerted becomes painful. Three measures will be
taken with the algometer on the same demarcated point
of the aforementioned muscle sites. The mean pressure
pain threshold will be determined from the three read-
ings of each of the three sites and the mean values will
be used in the statistical analysis. Readings will be taken
prior to stretching and warm-up, 1 minute after the ec-
centric contraction protocol as well as 1, 24, 48, 72 and
96 hours after the execution of the protocol.
Stretching and warm-up
Prior to the isokinetic protocol, the volunteers will per-
form three 60-second sets of active stretching of the knee
extensors of the non-dominant lower limb. The volunteers
will then perform a warm-up exercise consisting of pedal-
ing a stationary bike (Inbramed, Porto Alegre, RS, Brazil)
at 100 rpm for 5 minutes without load.
Isokinetic protocol: maximum voluntary contraction (MVC)
An isometric dynamometer will be used for the evalu-
ation of muscle function and the execution of the exer-
cise protocol. This instrument is considered the method
Figure 1 Flowchart of design, composition of groups and protocols in phases 1 and 2. MVC, maximum voluntary contraction.
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culoskeletal performance. Immediately after the stretch-
ing and warm-up exercises, the maximum voluntary
contraction (MVC) test will be performed. For such,
the volunteers will sit on the seat of the isokineticdynamometer (System 4, Biodex Medical Systems, Inc.,
Shirley, NY, USA) with an angle of 100° between the
trunk and hip and the non-dominant leg positioned with
the knee at 60° of flexion (0° corresponds to complete knee
extension) and attached to the seat of the dynamometer
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of hip flexion and will also be attached to the seat by a
strap. The volunteers will also be attached to the seat
of the dynamometer through the use of two straps
crossing the trunk. The volunteers will be instructed to
cross their arms over the trunk and the axis of the
dynamometer will be positioned parallel to the center of
the knee. The MVC test will consist of three 5-second iso-
metric contractions of the knee extensors of the non-
dominant leg. The highest torque value of the three
contractions (peak torque) will be used for the statistical
analysis. The choice of this parameter is due to the fact that
this variable reflects the maximum generation of force by
the muscle. Instructions on how to execute the test will be
given first and the volunteers will receive verbal encourage-
ment during the execution of the test. This test has demon-
strated reliability and reproducibility in a previous study
carried out [28]. The MVC will be performed immediately
(1 minute) after the eccentric contraction protocol as well
as 1, 24, 48, 72 and 96 hours after the eccentric contraction
protocol to evaluate post-exercise muscle recovery.
Low-level laser therapy (LLLT)
Specifications
A five-diode cluster laser device (each cluster with 0.0364
cm2; wavelength: 810 nm; power: 0, 100, 200 or 400 mW
in each diode; continuous light emission) (Thor Photome-
dicine, Chesham, UK) will be used for LLLT. The func-
tioning of the laser will be verified prior to the treatment
of each volunteer, with an inspection of the energy source,
application points and energy measurement. To ensure
blinding, the device will emit the same sounds regardless
of the programmed mode (active or placebo).
Variation of dose (phase 1)
In phase 1, the output power will be fixed at 200 mW
and LLLT will be applied 2 minutes prior to the pre-
exercise MVC test with the cluster in direct contact with
the skin at six distinct sites of the knee extensor muscu-
lature of the non-dominant limb (two medial, two lateral
and two central sites). As the cluster has five diodes and
six different sites will be irradiated, a total of 30 points
will be irradiated in the musculature. Based on the re-
sults of the randomization, the volunteers of the four ex-
perimental groups will receive the following doses:
Group A, 2 J per diode, 10 J on each application of the
cluster with 200 mW (10 seconds of irradiation at each
site), 60 J of total irradiated energy on the muscle (60
seconds of total irradiation time); Group B, 6 J per
diode, 30 J on each application of the cluster with 200
mW (30 seconds of irradiation at each site), 180 J of
total irradiated energy on the muscle (180 seconds of
total irradiation time); Group C, 10 J per diode, 50 J on
each application of the cluster with 200 mW (50 secondsof irradiation at each site), 300 J of total irradiated en-
ergy on the muscle (300 seconds of total irradiation
time); and Group D, 0 J per diode (placebo) (20 seconds
of irradiation at each site, 120 seconds of total time, but
without effective irradiation).
Variation of power (phase 2)
The aim of phase 2 is to determine the best power/ir-
radiation time (Watts/s) for use on humans to enhance
muscle recovery following physical exercise. For such,
the dose with the best results in phase 1 will be used
and the same methodological and evaluative measures
will be employed. Thus, only the power of the equip-
ment (and consequently irradiation time) will be varied
(100, 200, 400 or 0 mW). As energy (E) expressed in
Joules is equal to power (P) expressed in Watts multi-
plied by time (t) measured in seconds, different power
variations will lead to the same total energy delivered to
the tissue. A priori, if the best dose were determined to
be 10 J, the following would be the parameters:
 10 J = 0.1 W (100 mW) × 100 s
 10 J = 0.2 W (200 mW) × 50 s
 10 J = 0.4 W (400 mW) × 25 s
 10 J = 0.0 W (placebo, 60 s)
Isokinetic protocol: eccentric contractions
Precisely 3 minutes after the end of LLLT, the volunteers
will perform the eccentric contraction protocol, which will
consist of 75 eccentric isokinetic contractions of the knee
extensor musculature in the non-dominant leg (five sets of
15 repetitions, 30-second rest interval between sets) at a
velocity of 60°.seg-1 in both the eccentric and concentric
movements with a 60° range of motion (between 90° and
30° of knee flexion). At each contraction, the dynamom-
eter will automatically (passively) position the knee at 30°;
the dynamometer will then flex the knee until reaching
90°. The volunteers will be instructed to resist the knee
flexion movement imposed by the dynamometer with
maximum force. Instructions on how to execute the man-
euver will be given first and the volunteers will receive ver-
bal encouragement throughout the protocol. Despite the
diversity of protocols proposed for the execution of eccen-
tric exercises on isokinetic dynamometers, the protocol
described here was chosen based on a previous study car-
ried out [28] in which this method proved effective and re-
producible for the exercise-induced muscle damage.
Data analysis
The intention-to-treat analysis will be followed. The pri-
mary outcome will be peak torque obtained from MVC
at different time-points. Secondary outcomes will be bio-
chemical markers CK, LDH, IL-1β, IL-6, TNF-α, TBARS,
carbonylated proteins, CAT and SOD.
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and will be firstly tested regarding normal distribution
using Shapiro–Wilk test. ANOVA test with repeated
measurements for the time factor will be performed to test
between-groups differences (followed by the Bonferroni
post hoc test). The level of significance for the statistical
analysis will be set at 5% (P ≤0.05).
Discussion
In the proposed study, the ideal LLLT application dose
and power will be identified and the long-term effects of
LLLT on post-exercise muscle fatigue and musculoskel-
etal recovery will be evaluated. For such, evaluations will
be carried out of peak torque during MVC, late-onset
muscle pain will be determined and biochemical ana-
lyses will be performed to determine changes in markers
of inflammation, oxidative stress and muscle damage.
The inflammatory process is known to be a defensive re-
action against injury. This process has been extensively
studied in its different aspects. Briefly, the main inflam-
mation events are: 1) tissue injury; 2) the release of vaso-
active substances by the injured tissue; 3) vasodilatation;
4) leukocyte adherence; 5) the migration of leukocytes
from the blood stream to the injury site; and 6) tissue re-
pair. Thus, muscle inflammation is a natural conse-
quence of exercise-induced muscle damage [30].
Over time, LLLT exhibits a biphasic, dose–response
pattern. This means that intermediate doses within a
‘therapeutic window’ trigger stimulation effects in bio-
logical tissue, whereas doses outside this range do not
trigger any effects [31-34]. However, the therapeutic
window varies depending on the condition to be treated
[31]. Likewise, the power and irradiation time employed
are extremely important to obtaining the best results.
Thus, a short irradiation time and an output power that
is either too low or too high can lead to null results
[31,34]. Our intention, therefore, is to determine ideal
laser therapy application parameters capable of slowing
down the physiological muscle fatigue process, reducing
injuries or micro-injuries in skeletal muscle stemming
from physical exertion and accelerating post-exercise
muscle recovery. We believe that, unlike drug therapy,
LLLT has a biphasic dose–response pattern.
Trial status
At the time of manuscript submission, the volunteers
were being recruited.
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